Follow the people · Insider
Brandi Roberts
Brandi Roberts files insider transactions with the SEC as a chief financial officer of Definium Therapeutics (DFTX). We hold 1 disclosed purchase or sale filed since 17 June 2011, 1 of them in the last 90 days.
- Files forDFTX
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure12 August 2026
Positions held
10 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 3 February 2026 — 12 August 2026Chief Financial Officer · Definium Therapeutics (DFTX)5 Form 4 lines · source: SEC Form 4
- Filed 2 June 2025 — 2 June 2025Chief Financial Officer · Mind Medicine (MindMed) (MNMD)1 Form 4 line · source: SEC Form 4
- Filed 9 February 2022 — 2 December 2024Executive VP and CFO · Longboard Pharmaceuticals (LBPH)11 Form 4 lines · source: SEC Form 4
- Filed 29 December 2022 — 3 July 2024Director · TFF Pharmaceuticals (TFFP)6 Form 4 lines · source: SEC Form 4
- Filed 13 August 2019 — 17 March 2020CFO & SVP Finance · Lineage Cell Therapeutics (LCTX)2 Form 4 lines · source: SEC Form 4
- Filed 7 January 2019 — 30 June 2019CFO & SVP, Finance · Biotime (BTX)2 Form 4 lines · source: SEC Form 4
- Filed 22 January 2018 — 29 June 2018SVP & Chief Financial Officer · REVA Medical (RVA.AX)3 Form 4 lines · source: SEC Form 4
- Filed 18 September 2017 — 18 September 2017SVP & Chief Financial Officer · REVA Medical (RVA:AX)1 Form 4 line · source: SEC Form 4
- Filed 19 June 2013 — 20 January 2017Chief Financial Officer & SVP · Mast Therapeutics (MSTX)9 Form 4 lines · source: SEC Form 4
- Filed 15 June 2011 — 2 January 2013Chief Financial Officer & SVP · Adventrx Pharmaceuticals (ANX)3 Form 4 lines · source: SEC Form 4
Everything they disclosed
43 entries, newest first — one per disclosure report, one per Form 4 line- was granted 62,500 shares of Definium TherapeuticsSEC Form 412 August 2026Common Shares · traded 12 August 2026 · filed 12 August 2026
- ▼ sold on the open market 3,013 shares of Definium TherapeuticsSEC Form 426 June 2026Common Shares · traded 25 June 2026 · filed 26 June 2026
- was granted 62,500 shares of Definium TherapeuticsSEC Form 422 June 2026Common Shares · traded 22 June 2026 · filed 22 June 2026
- was granted 150,000 shares of Definium TherapeuticsSEC Form 45 February 2026Common Shares · traded 3 February 2026 · filed 5 February 2026
- was granted 150,000 shares of Definium TherapeuticsSEC Form 45 February 2026Common Shares · traded 3 February 2026 · filed 5 February 2026
- was granted 500,000 shares of Mind Medicine (MindMed) (a derivative holding)SEC Form 42 June 2025Stock Option (Right to Buy) · traded 2 June 2025 · filed 2 June 2025
- returned to the issuer 139,380 shares of Longboard Pharmaceuticals (a derivative holding)SEC Form 42 December 2024Employee Stock Option (right to buy) · traded 2 December 2024 · filed 2 December 2024
- returned to the issuer 90,000 shares of Longboard Pharmaceuticals (a derivative holding)SEC Form 42 December 2024Employee Stock Option (right to buy) · traded 2 December 2024 · filed 2 December 2024
- returned to the issuer 119,700 shares of Longboard Pharmaceuticals (a derivative holding)SEC Form 42 December 2024Employee Stock Option (right to buy) · traded 2 December 2024 · filed 2 December 2024
- returned to the issuer 90,580 shares of Longboard Pharmaceuticals (a derivative holding)SEC Form 42 December 2024Employee Stock Option (right to buy) · traded 2 December 2024 · filed 2 December 2024
- returned to the issuer 15,090 shares of Longboard Pharmaceuticals (a derivative holding)SEC Form 42 December 2024Restricted Stock Unit · traded 2 December 2024 · filed 2 December 2024
- returned to the issuer 7,900 shares of Longboard Pharmaceuticals (a derivative holding)SEC Form 42 December 2024Restricted Stock Unit · traded 2 December 2024 · filed 2 December 2024
- was granted 7,900 shares of Longboard Pharmaceuticals (a derivative holding)SEC Form 429 October 2024Retention Restricted Stock Units · traded 25 October 2024 · filed 29 October 2024
- was granted 3,165 shares of TFF Pharmaceuticals (a derivative holding)SEC Form 48 July 2024Stock Options (Right to Buy) · traded 3 July 2024 · filed 8 July 2024
- was granted 3,165 shares of TFF PharmaceuticalsSEC Form 48 July 2024Common Stock · traded 3 July 2024 · filed 8 July 2024
- was granted 5,333 shares of TFF Pharmaceuticals (a derivative holding)SEC Form 422 April 2024Restricted stock units · traded 18 April 2024 · filed 22 April 2024
- was granted 90,580 shares of Longboard Pharmaceuticals (a derivative holding)SEC Form 49 February 2024Stock Option (Right to Buy) · traded 8 February 2024 · filed 9 February 2024
- was granted 15,090 shares of Longboard PharmaceuticalsSEC Form 49 February 2024Common Stock · traded 8 February 2024 · filed 9 February 2024
- was granted 52,858 shares of TFF Pharmaceuticals (a derivative holding)SEC Form 44 December 2023Stock Options (Right to Buy) · traded 1 December 2023 · filed 4 December 2023
- ▲ bought on the open market 20,000 shares of TFF PharmaceuticalsSEC Form 415 August 2023Common Stock · traded 15 August 2023 · filed 15 August 2023
- was granted 119,700 shares of Longboard Pharmaceuticals (a derivative holding)SEC Form 410 February 2023Stock Option (Right to Buy) · traded 9 February 2023 · filed 10 February 2023
- was granted 20,968 shares of TFF Pharmaceuticals (a derivative holding)SEC Form 430 December 2022Stock Options (Right to Buy) · traded 29 December 2022 · filed 30 December 2022
- was granted 90,000 shares of Longboard Pharmaceuticals (a derivative holding)SEC Form 411 February 2022Stock Option (Right to Buy) · traded 9 February 2022 · filed 11 February 2022
- was granted 616,700 shares of Lineage Cell Therapeutics (a derivative holding)SEC Form 419 March 2020Employee Stock Option (Right to Buy) · traded 17 March 2020 · filed 19 March 2020
- ▲ bought on the open market 5,000 shares of Lineage Cell TherapeuticsSEC Form 415 August 2019Common Shares · traded 13 August 2019 · filed 15 August 2019
- was granted 150,000 shares of Biotime (a derivative holding)SEC Form 42 July 2019Employee Stock Option (Right to Buy) · traded 30 June 2019 · filed 2 July 2019
- was granted 500,000 shares of Biotime (a derivative holding)SEC Form 49 January 2019Option to Purchase Common Shares · traded 7 January 2019 · filed 9 January 2019
- ▲ bought on the open market 4,908 shares of REVA MedicalSEC Form 42 July 2018Common Stock · traded 29 June 2018 · filed 2 July 2018
- was granted 100,000 shares of REVA Medical (a derivative holding)SEC Form 423 January 2018Employee Stock Option (right to buy) · traded 22 January 2018 · filed 23 January 2018
- was granted 50,000 shares of REVA MedicalSEC Form 423 January 2018Common Stock (RSUs) · traded 22 January 2018 · filed 23 January 2018
- was granted 190,000 shares of REVA Medical (a derivative holding)SEC Form 419 September 2017Employee Stock Option (right to buy) · traded 18 September 2017 · filed 19 September 2017
- was granted 889,926 shares of Mast Therapeutics (a derivative holding)SEC Form 423 January 2017Restricted Stock Units · traded 20 January 2017 · filed 23 January 2017
- was granted 572,700 shares of Mast Therapeutics (a derivative holding)SEC Form 46 January 2016Employee Stock Option (Right to Buy) · traded 4 January 2016 · filed 6 January 2016
- was granted 444,400 shares of Mast Therapeutics (a derivative holding)SEC Form 412 June 2015Employee Stock Option (Right to Buy) · traded 11 June 2015 · filed 12 June 2015
- ▲ bought on the open market 20,000 shares of Mast TherapeuticsSEC Form 430 March 2015Common Stock · traded 26 March 2015 · filed 30 March 2015
- ▲ bought on the open market 18,000 shares of Mast TherapeuticsSEC Form 430 March 2015Common Stock · traded 27 March 2015 · filed 30 March 2015
- was granted 722,800 shares of Mast Therapeutics (a derivative holding)SEC Form 42 January 2015Stock Option (Right to Buy) · traded 2 January 2015 · filed 2 January 2015
- was granted 336,600 shares of Mast Therapeutics (a derivative holding)SEC Form 420 June 2014Stock Option (Right to Buy) · traded 19 June 2014 · filed 20 June 2014
- was granted 101,200 shares of Mast Therapeutics (a derivative holding)SEC Form 43 January 2014Employee Stock Option (Right to Buy) · traded 2 January 2014 · filed 3 January 2014
- was granted 301,250 shares of Mast Therapeutics (a derivative holding)SEC Form 421 June 2013Employee Stock Option (Right to Buy) · traded 19 June 2013 · filed 21 June 2013
- was granted 75,750 shares of Adventrx Pharmaceuticals (a derivative holding)SEC Form 43 January 2013Employee Stock Option (Right to Buy) · traded 2 January 2013 · filed 3 January 2013
- was granted 140,000 shares of Adventrx Pharmaceuticals (a derivative holding)SEC Form 49 December 2011Employee Stock Option (Right to Buy) · traded 8 December 2011 · filed 9 December 2011
- was granted 85,000 shares of Adventrx Pharmaceuticals (a derivative holding)SEC Form 417 June 2011Employee Stock Option (Right to Buy) · traded 15 June 2011 · filed 17 June 2011
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.